ROIVANT SCIENCES LTD. Payments for (Proceeds from) Other Investing Activities
ROIVANT SCIENCES LTD. (ROIV) reported Payments for (Proceeds from) Other Investing Activities of $2.52 million for the 12-month period ending 2026-03-31, per its 10-K filed 2026-05-20.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsForProceedsFromOtherInvestingActivities · last filed 2026-05-20
- ROIVANT SCIENCES LTD. payments for (proceeds from) other investing activities for the quarter ending 2026-03-31 was $0.00.
- ROIVANT SCIENCES LTD. payments for (proceeds from) other investing activities for the quarter ending 2025-03-31 was -$79.00K.
- ROIVANT SCIENCES LTD. payments for (proceeds from) other investing activities for the quarter ending 2024-12-31 was $0.00.
- ROIVANT SCIENCES LTD. payments for (proceeds from) other investing activities for the quarter ending 2024-09-30 was $0.00.
- ROIVANT SCIENCES LTD. payments for (proceeds from) other investing activities for fiscal 2026 was $2.52M.
- ROIVANT SCIENCES LTD. payments for (proceeds from) other investing activities for fiscal 2025 was -$79.00K.
- ROIVANT SCIENCES LTD. payments for (proceeds from) other investing activities for fiscal 2024 was -$8.59M.
- ROIVANT SCIENCES LTD. payments for (proceeds from) other investing activities for fiscal 2023 was -$702.00K.
| Period end | Payments for (Proceeds from) Other Investing Activities 3 month | Payments for (Proceeds from) Other Investing Activities 6 month | Payments for (Proceeds from) Other Investing Activities 9 month | Payments for (Proceeds from) Other Investing Activities 12 month |
|---|---|---|---|---|
| 2026-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $2.52M 10-K · filed 2026-05-20 | ||
| 2025-12-31 | $2.52M 10-Q · filed 2026-02-06 | |||
| 2025-03-31 | -$79.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | -$79.00K derived: sum of 2 quarters · filed 2026-05-20 | -$79.00K derived: sum of 3 quarters · filed 2026-05-20 | -$79.00K 10-K · filed 2026-05-20 |
| 2024-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | $0.00 derived: sum of 2 quarters · filed 2026-02-06 | $0.00 10-Q · filed 2026-02-06 | -$8.08M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | -$8.08M derived: sum of 3 quarters · filed 2026-05-20 | -$8.08M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-09 | -$8.08M derived: sum of 2 quarters · filed 2026-05-20 | -$8.08M derived: sum of 3 quarters · filed 2026-05-20 | -$8.08M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-03-31 | -$8.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | -$8.08M derived: sum of 2 quarters · filed 2026-05-20 | -$8.08M derived: sum of 3 quarters · filed 2026-05-20 | -$8.59M 10-K · filed 2026-05-20 |
| 2023-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-10 | -$3.00K derived: sum of 2 quarters · filed 2025-02-10 | -$511.00K 10-Q · filed 2025-02-10 | -$1.13M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-09-30 | -$3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-12 | -$511.00K 10-Q · filed 2024-11-12 | -$1.13M derived: sum of 3 quarters · filed 2025-05-29 | -$1.21M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-06-30 | -$508.00K 10-Q · filed 2024-08-09 | -$1.12M derived: sum of 2 quarters · filed 2025-05-29 | -$1.21M derived: sum of 3 quarters · filed 2025-05-29 | -$1.21M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-03-31 | -$614.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | -$702.00K derived: sum of 2 quarters · filed 2025-05-29 | -$702.00K derived: sum of 3 quarters · filed 2025-05-29 | -$702.00K 10-K · filed 2025-05-29 |
| 2022-12-31 | -$88.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-13 | -$88.00K derived: sum of 2 quarters · filed 2024-02-13 | -$88.00K 10-Q · filed 2024-02-13 | -$688.00K derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 | -$600.00K derived: sum of 3 quarters · filed 2023-11-13 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-14 | -$600.00K derived: sum of 2 quarters · filed 2023-08-14 | ||
| 2022-03-31 | -$600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | -$600.00K 10-K · filed 2023-06-28 | ||
| 2021-12-31 | $0.00 10-Q · filed 2023-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |